36,585 Shares in Indivior PLC $INDV Purchased by Sandro Wealth Management LLC

Sandro Wealth Management LLC acquired a new position in Indivior PLC (NASDAQ:INDV) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 36,585 shares of the company’s stock, valued at approximately $1,313,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Salomon & Ludwin LLC acquired a new stake in Indivior in the fourth quarter worth about $30,000. Harbor Capital Advisors Inc. increased its position in Indivior by 309.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after purchasing an additional 781 shares during the period. CWM LLC acquired a new position in shares of Indivior during the 3rd quarter worth about $25,000. Quarry LP acquired a new position in shares of Indivior during the 3rd quarter worth about $26,000. Finally, GAMMA Investing LLC grew its position in shares of Indivior by 544.6% during the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after buying an additional 1,013 shares during the period. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Indivior

In other Indivior news, Director Stuart A. Kingsley acquired 940 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were acquired at an average price of $31.86 per share, for a total transaction of $29,948.40. Following the acquisition, the director directly owned 5,582 shares of the company’s stock, valued at approximately $177,842.52. This trade represents a 20.25% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.74% of the stock is owned by company insiders.

Indivior Price Performance

NASDAQ:INDV opened at $37.66 on Friday. Indivior PLC has a fifty-two week low of $10.63 and a fifty-two week high of $40.02. The stock has a market capitalization of $4.59 billion, a PE ratio of 22.96 and a beta of 0.90. The business’s 50-day simple moving average is $31.84 and its 200-day simple moving average is $32.41.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The business had revenue of $317.00 million for the quarter. On average, research analysts expect that Indivior PLC will post 3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on INDV. HC Wainwright boosted their target price on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Weiss Ratings lowered Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, March 17th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. Finally, Northland Securities set a $50.00 target price on Indivior in a research report on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $39.33.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.